Abstract:Alzheimer's disease (AD) is the most common cause of dementia among older people. At present, there is no cure for the disease and as of now there are no early diagnostic tests for AD. There is an urgency to develop a novel promising biomarker for early diagnosis of AD. Using surface-enhanced laser desorption ionization-mass spectrometry SELDI-(MS) proteomic technology, we identified and purified a novel 11.7-kDa metal-binding protein biomarker whose content is increased in the cerebrospinal fluid (CSF) and in the brain of AD dementia subjects as a function of clinical dementia. Following purification and protein-sequence analysis, we identified and classified this biomarker as S100A7, a protein known to be involved in immune responses. Using an adenoviral- S100A7 expression system, we continued to examine the potential role of S100A7 in AD amyloid neuropathology in in vitro model of AD. We found that the expression of exogenous S100A7 in primary cortico-hippocampal neuron cultures derived from Tg2576 transgenic embryos inhibits the generation of beta-amyloid (A beta)(1-42) and A beta(1-40) peptides, coincidental with a selective promotion of "non- amyloidogenic'' alpha-secretase activity via promotion of ADAM (a disintegrin and metalloproteinase)-10. Finally, a selective expression of human S100A7 in the brain of transgenic mice results in significant promotion of alpha-secretase activity. Our study for the first time suggests that S100A7 may be a novel biomarker of AD dementia and supports the hypothesis that promotion of S100A7 expression in the brain may selectively promote alpha-secretase activity in the brain of AD precluding the generation of amyloidogenic peptides. If in the future we find that S1000A7 protein content in CSF is sensitive to drug intervention experimentally and eventually in the clinical setting, S100A7 might be developed as novel surrogate index (biomarker) of therapeutic efficacy in the characterization of novel drug agents for the treatment of AD.

S100A6 and Its Brain Ligands in Neurodegenerative Disorders

S100A4 in the Physiology and Pathology of the Central and Peripheral Nervous System

The S100B story: from biomarker to active factor in neural injury

Stress-Dependent Changes in the CacyBP/SIP Interacting Protein S100A6 in the Mouse Brain

The Role of S100A6 in Human Diseases: Molecular Mechanisms and Therapeutic Potential

S100A6: molecular function and biomarker role

Inflammatory role of S100A8/A9 in the central nervous system non-neoplastic diseases

S100B actions on glial and neuronal cells in the developing brain: an overview

The Janus face of glial-derived S100B: Beneficial and detrimental functions in the brain

S100B protein: general characteristics and pathophysiological implications in the Central Nervous System

Upregulation of calcium binding protein, S100A6, in activated astrocytes is linked to glutamate toxicity

S100b Gene Expression Pattern in Spinal Cords

The Role of the S100 Protein Family in Glioma

Distribution of a specific calcium-binding protein of the S100 protein family, S100A6 (calcyclin), in subpopulations of neurons and glial cells of the adult rat nervous system

S100A7:Biological properties and implications in diseases

A Role in Obesity and Diabetes?

Roles of S100A8, S100A9 and S100A12 in infection, inflammation and immunity

S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells

Analysis and prediction of structure and function of the related tumor protein S100A6

Probing the S100 protein family through genomic and functional analysis

S100a7, A Novel Alzheimer'S Disease Biomarker With Non-Amyloidogenic Alpha-Secretase Activity Acts Via Selective Promotion Of Adam-10